• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)
临床输血与检验

临床输血与检验 ›› 2020, Vol. 22 ›› Issue (5): 462-466.DOI: 10.3969/j.issn.1671-2587.2020.05.004

• 新型冠状病毒肺炎专题（三） • 上一篇    下一篇

重症新冠肺炎患者输注新冠恢复期血浆的免疫学相关指标变化

赵鸿雁, 刘更夫, 黄懋雯, 梅方超   

  1. 435000 鄂东医疗集团黄石市中心医院（湖北理工学院附属医院）输血科（赵鸿雁,刘更夫,梅方超）;
    宁波市北仑区人民医院检验科（黄懋雯）
  • 收稿日期:2020-04-27 出版日期:2020-10-20 发布日期:2020-10-16
  • 通讯作者: 梅方超,男,湖北黄石人,主管技师,硕士研究生,主要从事临床输血研究,（E-mail）280542194@qq.com。
  • 作者简介:赵鸿雁（1994-）,女,湖北黄石人,技师,硕士研究生,主要从事临床输血研究,（E-mail）554671360@qq.com。共同第一作者：刘更夫（1962-）,男,湖北黄石人,主任技师,本科,主要从事临床输血研究,（Tel）0714-6257596。共同第一作者：黄懋雯（1993-）,女,浙江宁波人,技师,硕士研究生,主要从事临床检验研究,（E-mail）huangmw616@163.com。

Immunological Changes of Plasma in the Recovery Period of New Crown in Patients with Severe New Crown Pneumonia

ZHAO Hong-yan, LIU Geng-fu, HUANG Mao-wen, et al   

  1. Huangshi Central Hospital, Huangshi 435000
  • Received:2020-04-27 Online:2020-10-20 Published:2020-10-16

PDF

1386

摘要： 目的 分析重症新冠肺炎患者输注新冠肺炎康复者恢复期血浆后的免疫学改变。 方法 收集我院8名重症新冠肺炎患者输注新冠肺炎康复者恢复期血浆相关数据,比较治疗前后患者IL-6、新冠特异性IgM和IgG抗体、淋巴细胞百分比、新冠肺炎病毒核酸检测的变化,记录输注期间和输注后输血不良反应。 结果 输注后第一天,淋巴细胞百分比较基线值下降了2.5%（P<0.01）;输注后第二天,平均新冠特异性IgG抗体水平较基线值上升了6.04 AU/mL（P<0.05）;特异性IgM抗体和淋巴细胞百分比未出现明显变化;输注一周后,62.5%的新冠肺炎患者核酸检测结果转阴;IL-6水平在输注前后无明显变化。8名重症新冠肺炎患者均无输血不良反应。 结论 恢复期血浆在重症新冠肺炎患者治疗中可能起到一定的治疗作用。

关键词: 新冠恢复期血浆, 重症新冠肺炎患者

Abstract: Objective To analyze the immunological changes of severe COVID-19 patients after infusion of convalescent plasma. Methods Eight severe COVID-19 patients in our hospital were infused with COVID-19 convalescent plasma. The changes of IL-6, COVID-19 virus specific IgM and IgG antibodies, lymphocyte percentage and COVID-19 virus nucleic acid detection were compared before and after treatment. Adverse reactions of transfusion occurred during and after transfusion were recorded. Results On the first day after infusion, the percentage of lymphocytes in the patient decreased by 2.5%（P<0.01）. On the second day after infusion, the level of COVID-19 virus specific IgG increased by 6.04 AU/mL （P<0.05）. There was no significant change in specific IgM and lymphocyte percentage. One week after infusion, 62.5% of COVID-19 patients turned a negative nucleic acid test result. There was no significant change in IL-6 level before and after infusion. There were no blood transfusion adverse reactions. Conclusion Convalescent plasma may play a certain role in the treatment of patients with severe COVID-19.

Key words: Novel coronavirus pneumonia convalescent plasma, Patients with severe novel coronavirus pneumonia

中图分类号: